Dementia Market: Growth Momentum Across 7MM to 2034 - DelveInsight

DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia Market Forecast
https://www.delveinsight.com/sample-request/dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Dementia Market Report:
• The Dementia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In September 2025, The FDA has approved an at-home, once-weekly maintenance injection of Leqembi for patients with early Alzheimer's disease. Leqembi (lecanemab-irmb) is a prescription therapy indicated for early-stage Alzheimer's, including mild cognitive impairment and mild dementia. The newly approved Leqembi IQLIK (pronounced "I Click") is a subcutaneous, once-weekly injection designed for home use, providing a more convenient maintenance option for patients who have completed 18 months of intravenous (IV) treatment.
• As of 2025, LEQEMBI and KISUNLA are the latest approved anti-amyloid therapies for early-stage Alzheimer's associated dementia. Symptomatic treatments like Donepezil, Rivastigmine, Galantamine, and Memantine remain widely used, primarily for Alzheimer's but also beneficial in Lewy body, Parkinson's disease dementia, and mixed types. However, other dementias types such as frontotemporal and vascular still lack approved targeted disease-modifying therapies.
• In April 2025, Alector, announced the completion of enrollment in PROGRESS-AD, a 76-week Phase II clinical trial. The study is evaluating the safety and efficacy of AL101 (GSK4527226) in slowing disease progression in individuals with early Alzheimer's disease.
• In January 2025, Eisai and Biogen announced that the US FDA approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab-irmb), authorizing a new IV maintenance dosing regimen of once every four weeks.
• The dementia treatment pipeline includes promising investigational therapies such as Masupirdine, Latozinemab (AL001), AL101 (GSK4527226), among others, reflecting ongoing efforts to address various forms and symptoms of the disease.
• According to WHO, approximately 55 million people worldwide are currently living with dementia. . Alzheimer's disease and other forms of dementia ranked as the 7th leading cause of death.
• As per the secondary analysis, globally, the number of people affected by dementia was estimated to have increased, largely due to population ageing
• Women are disproportionately affected by dementia, both directly and indirectly. Women experience higher disability-adjusted life years and mortality due to dementia.
• Key Dementia Companies: Biogen/Eisai, Eli Lilly and Company, Alector, Suven Life Sciences, Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others
• Key Dementia Therapies: LEQEMBI (lecanemab-irmb), KISUNLA (donanemab-azbt), Latozinemab (AL001), Masupirdine (SUVN-502), BAC, PNA1, Apabetalone, CY6463, Butylphthalide soft capsule, galantamine, Prospecta, donepezil hydrochloride (Aricept), SaiLuoTong capsule, Akatinol Memantine, Cerebrolysin, Cilostazol, risperidone, DatSCAN, and others
• The Dementia epidemiology based on age-specific cases analyzed that Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare
• The Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia pipeline products will significantly revolutionize the Dementia market dynamics.

Dementia Overview
Dementia is a progressive neurological disorder that affects memory, thinking, behavior, and the ability to perform daily activities. It is caused by damage to brain cells, leading to cognitive decline. Common types include Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal dementia. Symptoms include memory loss, confusion, difficulty in communication, and impaired reasoning. While there is no cure, treatments like medications, cognitive therapies, and lifestyle modifications can help manage symptoms and improve quality of life.

Get a Free sample for the Dementia Market Report:
https://www.delveinsight.com/report-store/dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dementia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dementia Epidemiology Segmentation:
The Dementia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Dementia
• Prevalent Cases of Dementia by severity
• Gender-specific Prevalence of Dementia
• Diagnosed Cases of Episodic and Chronic Dementia

Download the report to understand which factors are driving Dementia epidemiology trends @ Dementia Epidemiology Forecast
https://www.delveinsight.com/sample-request/dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dementia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia market or expected to get launched during the study period. The analysis covers Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dementia Therapies and Key Companies
• LEQEMBI (lecanemab-irmb): Biogen/Eisai
• KISUNLA (donanemab-azbt): Eli Lilly and Company
• Latozinemab (AL001): Alector
• Masupirdine (SUVN-502): Suven Life Sciences
• BAC: Charsire Biotechnology Corp
• PNA1: ProNeurogen Therapeutics
• Apabetalone: Resverlogix
• CY6463: Cyclerion Therapeutics
• Butylphthalide soft capsule: CSPC-NBP Pharma
• galantamine: Johnson & Johnson
• Prospecta: Materia Medica Holding
• donepezil hydrochloride (Aricept): Eisai Co., Ltd.
• SaiLuoTong capsule: Shineway Pharma
• Akatinol Memantine: Merz Pharma
• Cerebrolysin: Ever Neuro Pharma GmbH
• Cilostazol: Zhejiang Otsuka Pharma
• risperidone: Janssen, LP
• DatSCAN: GE Healthcare

Discover more about therapies set to grab major Dementia market share @ Dementia Treatment Market
https://www.delveinsight.com/sample-request/dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Dementia Market Drivers
• Rapidly Aging Global Population: Growth in the elderly population significantly increases dementia prevalence, expanding the diagnosed and treated patient base.
• Rising Awareness and Early Diagnosis: Improved public awareness, screening programs, and advances in neuroimaging and biomarkers are driving earlier detection and treatment initiation.
• Advancements in Disease-Modifying Therapies: Increasing R&D investment in disease-modifying treatments, including anti-amyloid and anti-tau therapies, is fueling market growth.
• Growing Healthcare Expenditure and Policy Support: Government initiatives, reimbursement programs, and national dementia strategies support improved access to diagnosis and treatment.
• Expansion of Digital Health and Care Technologies: Adoption of digital tools, remote monitoring, and cognitive assessment platforms is enhancing dementia management and care delivery.

Dementia Market Barriers
• Limited Efficacy of Available Treatments: Current therapies offer modest symptomatic benefits, limiting adoption and market confidence.
• High Development and Treatment Costs: Expensive clinical trials and high therapy costs pose reimbursement and accessibility challenges.
• Complex Disease Biology and Heterogeneity: Multiple dementia subtypes and overlapping pathologies complicate diagnosis, drug development, and regulatory approval.
• Safety and Tolerability Concerns: Adverse effects associated with emerging therapies may restrict broader clinical use.
• Ethical, Social, and Care Infrastructure Challenges: Caregiver burden, limited long-term care facilities, and regional disparities in healthcare access hinder optimal disease management.

Scope of the Dementia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dementia Companies: Biogen/Eisai, Eli Lilly and Company, Alector, Suven Life Sciences, Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others
• Key Dementia Therapies: LEQEMBI (lecanemab-irmb), KISUNLA (donanemab-azbt), Latozinemab (AL001), Masupirdine (SUVN-502), BAC, PNA1, Apabetalone, CY6463, Butylphthalide soft capsule, galantamine, Prospecta, donepezil hydrochloride (Aricept), SaiLuoTong capsule, Akatinol Memantine, Cerebrolysin, Cilostazol, risperidone, DatSCAN, and others
• Dementia Therapeutic Assessment: Dementia current marketed and Dementia emerging therapies
• Dementia Market Dynamics: Dementia market drivers and Dementia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dementia Unmet Needs, KOL's views, Analyst's views, Dementia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.